BioSig Technologies today announced that it has appointed Gray Fleming as chief commercial officer.
Most recently, Fleming served as chief commercial officer at Carecube, which is developing a temporary and scalable negative pressure isolation technology.
“I am extremely excited to be returning to the electrophysiology arena and, most importantly, dedicating effort and energy towards supporting the fight against AFib. My experience offers me the luxury of understanding that without the signal, the procedure cannot be possible. I look forward to leading the team that can provide the cleanest signal in every electrophysiology laboratory in the world,” Fleming said in a news release.
Fleming has more than 20 years of experience in the healthcare industry. Prior to joining the company, he worked at Abbott Laboratories and St. Jude Medical. He held numerous commercial leadership positions at Abbott, including VP of cardiac sales.
“We are pleased to welcome Gray to the team as we enter an advanced phase of targeted market release within our commercial growth strategy. Gray’s second-to-none knowledge of electrophysiology space and his impressive track record in capturing and growing market share in all regions of our strategic geographic interest is well aligned with our mission to bring our signal processing technology to as many hospitals as possible in the coming years,” CEO Kenneth Londoner said. “We are closing 2021 with an immense amount of knowledge derived from nearly two thousand patient procedures, and we look forward to applying these insights to a high-impact commercial strategy that we will deliver under Gray’s leadership.”